Workflow
Ascletis Presents Full Analysis of Phase Ib Study of ASC30 Oral Tablet, Phase Ib Study of ASC30 Injection, and Preclinical Study of Combination of ASC31 and ASC47 at ObesityWeek® 2025
Prnewswire· 2025-11-05 00:10
-Presentations further highlight the promising efficacy and safety profiles of Ascletis' diverse obesity pipeline and validate its proprietary Artificial Intelligence-Assisted Structure-Based Drug Discovery (AISBDD) and Ultra-Long-Acting Platform (ULAP) technologies. HONG KONG, Nov. 4, 2025 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces multiple poster presentations of the full analysis of the Phase Ib study of ASC30 once-daily oral tablet, Phase Ib study of ASC30 once-monthly injec ...
Tempus AI signals sustained 25% genomics growth target through 2028 while achieving first positive adjusted EBITDA (NASDAQ:TEM)
Seeking Alpha· 2025-11-05 00:07
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...
Global Payments Inc. (NYSE:GPN) Maintains Strong Position in Payment Processing Industry
Financial Modeling Prep· 2025-11-05 00:05
Core Viewpoint - Global Payments Inc. demonstrates strong financial performance and growth potential, supported by a positive outlook from Raymond James, which has raised the price target for the stock. Financial Performance - The company reported adjusted earnings per share (EPS) of $3.26, exceeding the Zacks Consensus Estimate of $3.23, marking a 12% increase compared to the previous year [2] - Revenue for the third quarter rose by 3% to $2.4 billion, driven by strong performance in the Merchant and Issuer Solutions segments, surpassing consensus expectations by 0.9% [3] - The operating margin expanded by 110 basis points to 45%, attributed to reduced expenses and gains in core segments [3] Stock Performance - The current stock price for GPN is $79.51, reflecting an increase of approximately 3.12% or $2.41 [4] - Over the past year, the stock has fluctuated between a high of $120 and a low of $65.93, with a market capitalization of approximately $19.29 billion [4] - Raymond James reaffirmed its "Outperform" rating for GPN and raised the price target from $100 to $105 [5]
Cricut, Inc. (CRCT) Surpasses Q3 Earnings and Revenue Estimates
ZACKS· 2025-11-05 00:05
Core Insights - Cricut, Inc. reported quarterly earnings of $0.1 per share, exceeding the Zacks Consensus Estimate of $0.05 per share, marking a 100% earnings surprise [1] - The company achieved revenues of $170.44 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 7.91% and showing a year-over-year increase from $167.89 million [2] Earnings Performance - Cricut has surpassed consensus EPS estimates in all four of the last quarters, indicating strong earnings performance [2] - The company had an earnings surprise of +83.33% in the previous quarter, where it reported earnings of $0.11 per share against an expectation of $0.06 [1][2] Future Outlook - The current consensus EPS estimate for the upcoming quarter is $0.01 on revenues of $197.14 million, while for the current fiscal year, it is $0.28 on revenues of $689.83 million [7] - The earnings outlook and revisions will be crucial for understanding the stock's future performance [4][6] Industry Context - Cricut operates within the Zacks Technology Services industry, which is currently ranked in the top 35% of over 250 Zacks industries, suggesting a favorable industry environment [8] - The performance of Cricut's stock may be influenced by the overall outlook for the industry, as higher-ranked industries tend to outperform lower-ranked ones significantly [8]
Hyster-Yale (HY) Reports Q3 Loss, Tops Revenue Estimates
ZACKS· 2025-11-05 00:05
Core Insights - Hyster-Yale reported a quarterly loss of $0.09 per share, missing the Zacks Consensus Estimate of $0.03, and a significant decline from earnings of $0.97 per share a year ago, indicating an earnings surprise of -400.00% [1] - The company generated revenues of $979.1 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 2.45%, but down from $1.02 billion year-over-year [2] - Hyster-Yale shares have decreased approximately 30% year-to-date, contrasting with the S&P 500's gain of 16.5% [3] Earnings Outlook - The future performance of Hyster-Yale's stock will largely depend on management's commentary during the earnings call and the revisions of earnings estimates [3][4] - The current consensus EPS estimate for the upcoming quarter is $0.36 on revenues of $942.85 million, and for the current fiscal year, it is $0.75 on revenues of $3.77 billion [7] Industry Context - The Manufacturing - Construction and Mining industry, to which Hyster-Yale belongs, is currently ranked in the top 39% of over 250 Zacks industries, suggesting a favorable outlook compared to the bottom 50% [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked using tools like the Zacks Rank [5][6]
CeriBell, Inc. (CBLL) Reports Q3 Loss, Beats Revenue Estimates
ZACKS· 2025-11-05 00:05
Group 1 - CeriBell, Inc. reported a quarterly loss of $0.37 per share, better than the Zacks Consensus Estimate of a loss of $0.43, and an improvement from a loss of $1.85 per share a year ago, resulting in an earnings surprise of +13.95% [1] - The company posted revenues of $22.59 million for the quarter ended September 2025, exceeding the Zacks Consensus Estimate by 3.65%, and showing an increase from $17.19 million in the same quarter last year [2] - CeriBell, Inc. has surpassed consensus EPS estimates three times over the last four quarters and has topped consensus revenue estimates four times in the same period [2] Group 2 - The stock has underperformed, losing about 56.2% since the beginning of the year, while the S&P 500 has gained 16.5% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.42 on revenues of $23.33 million, and for the current fiscal year, it is -$1.55 on revenues of $86.82 million [7] - The Zacks Industry Rank for Medical - Products is in the bottom 41% of over 250 Zacks industries, indicating potential challenges for stock performance [8]
Mistras (MG) Beats Q3 Earnings and Revenue Estimates
ZACKS· 2025-11-05 00:05
Core Insights - Mistras reported quarterly earnings of $0.46 per share, exceeding the Zacks Consensus Estimate of $0.26 per share, and showing a year-over-year increase from $0.20 per share [1] - The company achieved revenues of $195.55 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 5.31% and increasing from $182.69 million a year ago [2] - Mistras has surpassed consensus EPS estimates three times over the last four quarters and topped revenue estimates two times in the same period [2] Earnings Performance - The earnings surprise for the recent quarter was +76.92%, following a previous surprise of +11.76% in the prior quarter [1][2] - The current consensus EPS estimate for the upcoming quarter is $0.23, with expected revenues of $177.33 million, and for the current fiscal year, the estimate is $0.67 on revenues of $710.04 million [7] Stock Performance and Outlook - Mistras shares have increased by approximately 5.9% since the beginning of the year, while the S&P 500 has gained 16.5% [3] - The company's Zacks Rank is currently 3 (Hold), indicating expected performance in line with the market in the near future [6] Industry Context - Mistras operates within the Zacks Electronics - Miscellaneous Products industry, which is currently ranked in the top 22% of over 250 Zacks industries [8] - The performance of Mistras may be influenced by the overall outlook for the industry, as top-ranked industries tend to outperform lower-ranked ones significantly [8]
Omdia: Display glass revenue reached a record high of JPY 270 billion in 3Q 2025
Businesswire· 2025-11-05 00:05
LONDON--(BUSINESS WIRE)-- #Display--Display glass revenue reached a record high of JPY 270 billion in the third quarter of 2025, driven by increases in both price and demand, according to new research from Omdia. This revenue represents a 5% quarter-over-quarter (QoQ) increase and 14% year-over-year (YoY) increase. Display glass is still traded in Japanese yen. Strong revenue performance in 3Q25 reflects a significant strategic shift in the industry. After a severe recession in 2011, glass makers endured. ...
Tesla's UK car sales halve in October, New Automotive data shows
Reuters· 2025-11-05 00:03
Tesla's UK car sales halved year-over-year in October, data from research group New AutoMotive showed on Wednesday, echoing the steep falls the U.S. electric vehicle maker saw in other European countr... ...
Kratos (KTOS) Reports Q3 Earnings: What Key Metrics Have to Say
ZACKS· 2025-11-05 00:01
Core Insights - Kratos (KTOS) reported $347.6 million in revenue for Q3 2025, a 26% year-over-year increase, with an EPS of $0.14 compared to $0.11 a year ago, exceeding both revenue and EPS estimates [1][4] Revenue Breakdown - Product sales reached $230.2 million, surpassing the average estimate of $191.59 million, reflecting a 33.8% year-over-year increase [4] - Unmanned Systems generated $87.2 million, exceeding the estimated $77.18 million, marking a 35.8% increase from the previous year [4] - Kratos Government Solutions reported $260.4 million, above the $248.03 million estimate, representing a 23% year-over-year growth [4] - Service revenues totaled $117.4 million, below the average estimate of $133.04 million, with a 13% increase year-over-year [4] Profitability Metrics - Gross profit from service revenues was $26.2 million, lower than the $33.11 million estimate [4] - Gross profit from product sales was $50.9 million, exceeding the $44.6 million estimate [4] - Operating income for Kratos Government Solutions was $13.7 million, below the $16.75 million estimate [4] Stock Performance - Kratos shares have returned -9.1% over the past month, contrasting with the Zacks S&P 500 composite's +2.1% change, but the stock holds a Zacks Rank 2 (Buy), indicating potential for outperformance in the near term [3]